Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Payables (2020 - 2025)

Pulse Biosciences has reported Payables over the past 6 years, most recently at $3.0 million for Q3 2025.

  • Quarterly results put Payables at $3.0 million for Q3 2025, up 72.44% from a year ago — trailing twelve months through Sep 2025 was $3.0 million (up 72.44% YoY), and the annual figure for FY2024 was $1.7 million, down 8.88%.
  • Payables for Q3 2025 was $3.0 million at Pulse Biosciences, up from $2.7 million in the prior quarter.
  • Over the last five years, Payables for PLSE hit a ceiling of $4.6 million in Q2 2021 and a floor of $1.4 million in Q3 2023.
  • Median Payables over the past 5 years was $2.1 million (2022), compared with a mean of $2.4 million.
  • Biggest five-year swings in Payables: skyrocketed 205.78% in 2021 and later plummeted 57.22% in 2022.
  • Pulse Biosciences' Payables stood at $1.8 million in 2021, then skyrocketed by 35.62% to $2.5 million in 2022, then decreased by 26.27% to $1.8 million in 2023, then fell by 8.88% to $1.7 million in 2024, then surged by 78.0% to $3.0 million in 2025.
  • The last three reported values for Payables were $3.0 million (Q3 2025), $2.7 million (Q2 2025), and $2.4 million (Q1 2025) per Business Quant data.